July 18th 2024

Introducing NUVISAN – a CARE Industry organisation

Introducing NUVISAN – a CARE Industry organisation

Founded in Europe in 1989 as an independent, family-owned contract research organization (CRO), NUVISAN was set up with a clear purpose: to leverage science to foster positive change and enhance the lives of patients. Initially providing bioanalytical laboratory services and PK/PD studies, the company later expanded to other areas, such as early discovery, safety testing, clinical trial management, and regulatory support. It has grown significantly since its founding and has expanded its services and capabilities to meet the changing needs of its clients.

Operating under the name NUVISAN since 2010, ALS Limited, the global leader in testing, acquired NUVISAN on April 1, 2024, forming the most advanced drug discovery and development organization and providing solutions across continents. NUVISAN is a fully integrated contract research and development and manufacturing organization (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. These include:

• Target Identification and Validation
• Target-to-Lead
• Lead-to-Candidate
• Preclinical
• Clinical

Why did NUVISAN choose to get involved in CARE?

NUVISAN chose to get involved in order to support the development of therapeutics in addressing the current or future coronavirus outbreaks. The CARE consortium offered the exciting opportunity for NUVISAN to team up with renowned research organisations jointly discovering and developing new treatment options to treat the current and future coronavirus outbreaks.

What has NUVISAN delivered for CARE?

In addition to our initiator role for the CARE project and bringing different expertise in medicinal chemistry (Work Package 3) and in vitro ADMET compound profiling (Work Package 6) into the team, NUVISAN is a project lead for a joint Hit-2-Lead project together with Servier (high throughput screening), Merck and Takeda (synthesis) and Iktos (AI, design), KU Leuven and LUMC (antiviral assays), Université d’Aix-Marseille (biochemical & biophysical assays), Helmholtz-Zentrum Für Infektionsforschung Gmbh and The Institute of Virology and Immunology (in vivo compound profiling).

These collaborative efforts have now achieved an in vivo proof-of-concept and the project is moved into lead optimization phase.

For more information about the different work packages, please click here

What benefits has NUVISAN enjoyed through participating in CARE?

Nico Brӓuer, NUVISAN PI for CARE comments: “We are delighted to be engaging with so many globally renowned research institutions and pharmaceutical companies in this impactful and exciting project. While collaborating on this joint endeavour, we continue to discover new ideas and unlock scientific innovation through extensive knowledge exchange and discussions with other members. Together, we can accelerate the development and utilization of effective therapies for patients around the world.”

In addition to Nico, the NUVISAN team includes